1. Home
  2. SRRK vs KGS Comparison

SRRK vs KGS Comparison

Compare SRRK & KGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRRK
  • KGS
  • Stock Information
  • Founded
  • SRRK 2012
  • KGS 2011
  • Country
  • SRRK United States
  • KGS United States
  • Employees
  • SRRK N/A
  • KGS N/A
  • Industry
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • KGS
  • Sector
  • SRRK Health Care
  • KGS
  • Exchange
  • SRRK Nasdaq
  • KGS Nasdaq
  • Market Cap
  • SRRK 4.2B
  • KGS 3.6B
  • IPO Year
  • SRRK 2018
  • KGS 2023
  • Fundamental
  • Price
  • SRRK $43.12
  • KGS $47.38
  • Analyst Decision
  • SRRK Strong Buy
  • KGS Strong Buy
  • Analyst Count
  • SRRK 7
  • KGS 11
  • Target Price
  • SRRK $40.43
  • KGS $39.36
  • AVG Volume (30 Days)
  • SRRK 1.1M
  • KGS 976.6K
  • Earning Date
  • SRRK 11-12-2024
  • KGS 03-05-2025
  • Dividend Yield
  • SRRK N/A
  • KGS 3.46%
  • EPS Growth
  • SRRK N/A
  • KGS N/A
  • EPS
  • SRRK N/A
  • KGS 0.26
  • Revenue
  • SRRK N/A
  • KGS $1,075,772,000.00
  • Revenue This Year
  • SRRK N/A
  • KGS $39.35
  • Revenue Next Year
  • SRRK N/A
  • KGS $16.29
  • P/E Ratio
  • SRRK N/A
  • KGS $182.43
  • Revenue Growth
  • SRRK N/A
  • KGS 33.77
  • 52 Week Low
  • SRRK $6.76
  • KGS $21.39
  • 52 Week High
  • SRRK $46.19
  • KGS $47.73
  • Technical
  • Relative Strength Index (RSI)
  • SRRK 57.37
  • KGS 74.09
  • Support Level
  • SRRK $38.72
  • KGS $41.32
  • Resistance Level
  • SRRK $45.15
  • KGS $44.43
  • Average True Range (ATR)
  • SRRK 2.33
  • KGS 1.38
  • MACD
  • SRRK -0.32
  • KGS 0.47
  • Stochastic Oscillator
  • SRRK 73.28
  • KGS 95.53

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

About KGS Kodiak Gas Services Inc.

Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Compression Operations and Other Services. Compression Operations consist of operating company-owned and customer-owned compression infrastructure for customers, pursuant to fixed-revenue contracts to enable the production, gathering and transportation of natural gas and oil. Other Services consist of a full range of contract services to support the needs of customers, including station construction, maintenance and overhaul and other ancillary time and material-based offerings.

Share on Social Networks: